Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract

被引:86
作者
Vang, R
Whitaker, BP
Farhood, AI
Silva, EG
Ro, JY
Deavers, MT
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[2] Univ Texas, Sch Med, Dept Pathol, Houston, TX 77030 USA
关键词
immunohistochemistry; clear cell carcinoma; ovary; endometrium; uterus; vagina; bladder; urethra; gynecologic; urologic; keratin; CK7; CK20; HER-2/neu;
D O I
10.1097/00004347-200107000-00008
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Clear cell carcinoma of the gynecologic tract has been defined in terms of its clinical and histologic features; however, its immunophenotypic profile has not been fully characterized. Seventeen cases of primary clear cell carcinoma from various sites within the female genital tract (11 ovary, 5 uterus, 1 vagina) were analyzed by immunohistochemistry. These turners were assessed for the expression of cytokeratin 7 (CK7), cytokeratin 20 (CK20), low and high molecular weight cytokeratins (CAM5.2 and 34 beta E12, respectively), carcinoembryonic antigen (CEA), Leu-MI, vimentin, estrogen receptor (ER), progesterone receptor (PR), bcl-2, p53, HER-2/neu, and CA-125. The characteristic immunoprofile for all sites was positivity fur CK7, CAM5.2, 34 beta E12, CEA, Leu-Ml, vimentin, bcl-2, p53, and CA-125; variably positivity for ER and HER-2/neu; and negativity for CK20 and PR. For comparison, two cases of urologic clear cell carcinoma (1 bladder, I urethra) were also studied, and their profile was found to be similar to the gynecologic cases. Aside from minor differences, clear cell carcinoma appears to have the same immunophenotype regardless of whether it originates in the endometrium, ovary, or genitourinary tract. Much of its profile is similar to other gynecologic adenocarcinomas, but some of the markers studied may be useful in the differential diagnosis of this tumor.
引用
收藏
页码:252 / 259
页数:8
相关论文
共 32 条
[1]  
Berezowski K, 1996, MODERN PATHOL, V9, P426
[2]  
Boyd J, 1996, CANCER-AM CANCER SOC, V77, P507, DOI 10.1002/(SICI)1097-0142(19960201)77:3<507::AID-CNCR12>3.0.CO
[3]  
2-8
[4]   IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN AND PROGESTERONE-RECEPTOR CONTENT IN 183 PATIENTS WITH ENDOMETRIAL CARCINOMA .1. CLINICAL AND HISTOLOGIC CORRELATIONS [J].
CARCANGIU, ML ;
CHAMBERS, JT ;
VOYNICK, IM ;
PIRRO, M ;
SCHWARTZ, PE .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 94 (03) :247-254
[5]   CARCINOEMBRYONIC ANTIGEN (CEA) AND CARBOHYDRATE DETERMINANT 19-9 (CA 19-9) LOCALIZATION IN 121 PRIMARY AND METASTATIC OVARIAN-TUMORS - AN IMMUNOHISTOCHEMICAL STUDY WITH THE USE OF MONOCLONAL-ANTIBODIES [J].
CHARPIN, C ;
BHAN, AK ;
ZURAWSKI, VR ;
SCULLY, RE .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1982, 1 (03) :231-245
[6]  
CHOR PJ, 1993, MODERN PATHOL, V6, P225
[7]  
Diebold J, 1996, AM J CLIN PATHOL, V105, P341
[8]   The histogenesis of clear cell adenocarcinoma of the lower urinary tract: Case series and review of the literature [J].
Drew, PA ;
Murphy, WM ;
Civantos, F ;
Speights, VO .
HUMAN PATHOLOGY, 1996, 27 (03) :248-252
[9]   IMMUNOHISTOCHEMISTRY OF ENDOMETRIAL STROMAL SARCOMA [J].
FARHOOD, AI ;
ABRAMS, J .
HUMAN PATHOLOGY, 1991, 22 (03) :224-230
[10]   p53 Expression as a prognostic indicator of 5-year survival in endometrial cancer [J].
Geisler, JP ;
Geisler, HE ;
Wiemann, MC ;
Zhou, Z ;
Miller, GA ;
Crabtree, W .
GYNECOLOGIC ONCOLOGY, 1999, 74 (03) :468-471